Waters (Waters) Cash, Cash Equivalents, Marketable Securities : $396 Mil (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Waters Cash, Cash Equivalents, Marketable Securities?

Waters's quarterly cash, cash equivalents, marketable securities increased from Jun. 2023 ($330.58 Mil) to Sep. 2023 ($337.31 Mil) and increased from Sep. 2023 ($337.31 Mil) to Dec. 2023 ($395.97 Mil).

Waters's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($569.29 Mil) to Dec. 2022 ($481.39 Mil) and declined from Dec. 2022 ($481.39 Mil) to Dec. 2023 ($395.97 Mil).

Waters Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Waters's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Waters Cash, Cash Equivalents, Marketable Securities Chart

Waters Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

337.14

443.15

569.29

481.39

395.97

Waters Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															481.39	486.96	330.58	337.31	395.97

Waters Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Waters (NYSE:WAT) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Waters Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Waters's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Waters (Waters) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Waters Corp (NYSE:WAT) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

WAT:Mexico WAZ:Germany

Address

34 Maple Street, Milford, MA, USA, 01757

Website

https://www.waters.com

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2022, Waters generated 59% from pharmaceutical customers, 31% from industrial clients, and 10% from academic/government institutions.

Executives

Christopher A Kuebler	director	210 CARNEGIE CENTER, PRINCETON NJ 08540
Richard H Fearon	director	1239 GERBING ROAD, AMELIA ISLAND FL 32034
Edward Conard	director
Daniel J. Brennan	director	BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Mark P Vergnano	director	1007 MARKET STREET, WILMINGTON DE 19898
Gary E Hendrickson	director	1101 THIRD STREET SOUTH, MINNEAPOLIS MN 55415
John M Ballbach	director
Linda Baddour	director	PRA INTERNATIONAL, 12120 SUNSET HILLS ROAD, SUITE 600, RESTON VA 20190
Michael J Berendt	director
Thomas P Salice	director
Wei Jiang	director	34 MAPLE STREET, MILFORD MA 01757
Amol Chaubal	officer: SVP and Chief Financial Office	113 HARTWELL AVE, C/O QUANTERIX CORPORATION, LEXINGTON MA 02421
Jianqing Bennett	officer: SVP TA Instruments Division	34 MAPLE STREET, MILFORD MA 01757
Joann A Reed	director	C/O AMERICAN TOWER CORP, 116 HUNTINGTON AVENUE, BOSTON MA 02116
Belinda Hyde	officer: SVP, Global Human Resources	13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277